Policy & Regulation
BeiGene Forms Strategic Alliance with Ontada to Improve US Community Oncology Care
16 August 2022 - - Chinese biotechnology company BeiGene (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235) has forged a strategic agreement with Ontada, a McKesson business offering technology and actionable real-world research, education, and evidence in oncology, to improve US community oncology care through the development of real-world evidence data, tools, and insights to help increase access to affordable, cutting-edge therapies, the company said.

The partnership will be led by Ontada and focus on accelerating the development and implementation of RWE to improve community education on the financial impact and value of oncolytics as well as improve patient access to oncology medicines.

As part of the collaboration, the companies will optimize the use of RWE to communicate value across key stakeholders including patients, providers, and payers; develop timely education on emerging science and therapeutic differentiation; and collaborate to advance use of RWE in healthcare and regulatory decision making to increase timely and affordable patient access to life-saving oncology therapies.

Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer.

It is part of healthcare services firm McKesson Corp.